IN THIS ISSUE

Editor’s Memo
Peter Wehrwein
Medication Management
Thomas Reinke
Pharma and Trump administration officials decry them as backroom deals. But payers and PBMs say rebates are an important negotiating tool with drugmakers. Take it away and drug expenditure will go up even faster.
Viewpoint
Maggie Alston
Bruce Pyenson
They can work, but pharma will need to master the intricacies of adherence metrics, real-world outcomes, and sampling.
Viewpoint
Zachary Hafner
News & Commentary
News & Commentary

A blueprint for high-volume, high-quality lung cancer screening that is detecting cancer earlier—and helping to save lives

Clinical Brief

Multiple Sclerosis: New Perspectives on the Patient Journey–2019 Update
Summary of an Actuarial Analysis and Report